Mithra Pharmaceuticals SA / Fundamentals
Income statement
- Net revenue
€107.15M - Cost of goods sold
€65.73M - Gross profit
€41.43M - SG&A expenses
€16.98M - R&D expenses
€127.21M - EBITDA
-€70.34M - D&A
€24.15M - EBIT
-€103.26M - Interest expenses
€46.32M - EBT
-€175.86M - Tax expenses
€57.27M - Net income
-€233.12M
Cash flow statement
- Net deferred tax
€28.89M - Non-cash items
€147.53M - Changes in working capital
-€42.84M - Operating cash flow
-€68.87M - Capex
€30.95M - Other investing cash flow
-€10.00M - Net investing cash flow
-€22.04M - Total cash dividends paid
€0.00 - Issuance of common stock
€52.54M - Debt repayment
-€20.38M - Other financing cash flow
€90.07M - Net financing cash flow
€67.19M - Foreign exchange effects
-€182.00K - Net change in cash
-€23.89M - Cash at end of period
€8.98M - Free cash flow
-€37.91M
Balance sheet
- Cash and cash equivalents
€8.98M - Cash and short-term investments
€8.98M - Total receivables
€36.09M - Inventory
€48.29M - Other current assets
€47.00K - Total current assets
€93.41M - Property, plant & equipment
€51.49M - Goodwill
€5.23M - Intangible assets
€108.71M - Long-term investments
€16.02M - Other non-current assets
€11.69M - Total non-current assets
€193.14M - Total assets
€286.55M - Accounts payable
€59.07M - Short-term debt
€33.15M - Other current liabilities
€9.25M - Total current liabilities
€103.98M - Long-term debt
€179.16M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€106.66M - Total non-current liabilities
€285.82M - Total liabilities
€389.80M - Common stock
€50.59M - Retained earnings
-€589.29M - Other equity
€10.59M - Total equity
-€103.26M - Total liabilities and shareholders' equity
€286.55M
Company information
- Market capitalization
€14.45M - Employees
270 - Enterprise Value
€211.34M
Company ratios
- Gross margin
-
38.7% Even with peer group: 37.3% - EBITDA margin
-
-65.6% Much worse than peer group: -6.4% - EBIT margin
-
-96.4% Much worse than peer group: -15.2% - EBT margin
-
-164.1% Much worse than peer group: -16.6% - Net margin
-
-217.6% Much worse than peer group: -17.0% - ROE
-
225.8% Much worse than peer group: 469.4% - ROA
-
-81.4% Much worse than peer group: 43.0% - Asset turnover
-
37.4% Much worse than peer group: 1,051.7% - FCF margin
-
-93.2% Much worse than peer group: -23.3% - FCF yield
-690.7% - Efficiency ratio
165.6% - Net sales per employee
-
€396.86K - Net income per employee
-
-€863.41K